Dynavax Technologies Corp...

AI Score

XX

Unlock

13.66
-0.06 (-0.44%)
At close: Mar 28, 2025, 3:59 PM
13.68
0.11%
After-hours: Mar 28, 2025, 04:20 PM EDT

Company Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.

The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt.

Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp.

The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.

Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Dynavax Technologies Corporation
Dynavax Technologies Corporation logo
Country United States
IPO Date Feb 19, 2004
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 405
CEO Ryan Spencer

Contact Details

Address:
2100 Powell Street
EmeryVille, California
United States
Website https://www.dynavax.com

Stock Details

Ticker Symbol DVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001029142
CUSIP Number 268158201
ISIN Number US2681582019
Employer ID 33-0728374
SIC Code 2834

Key Executives

Name Position
Ryan Spencer Chief Executive Officer & Director
David F. Novack President & Chief Operating Officer
Kelly MacDonald CPA Senior Vice President, Principal Accounting Officer & Chief Financial Officer
Donn Casale Senior Vice President & Chief Commercial Officer
Dr. Dong Yu Senior Vice President of Research
Dr. Robert Janssen M.D. Chief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs
Eric Frings Vice President, Site Head & MD for Dynavax GmbH
Jeff P. Coon Senior Vice President & Chief Human Resources Officer
John L. Slebir Senior Vice President & General Counsel
Paul Cox Vice President of Investor Relations & Corporate Communications

Latest SEC Filings

Date Type Title
Mar 26, 2025 4 Filing
Mar 20, 2025 4 Filing
Mar 13, 2025 8-K Current Report
Mar 10, 2025 4 Filing
Mar 10, 2025 DFAN14A Filing
Mar 06, 2025 8-K Current Report
Feb 21, 2025 4 Filing
Feb 20, 2025 4 Filing
Feb 20, 2025 4 Filing
Feb 20, 2025 4 Filing